Robert Barrow, Chief Executive Officer at Definium Therapeutics, Inc. (DFTX), sold 31,550 shares at $36.57 ($1.2M) on 2026-09-25, disclosed to the SEC on 2026-09-29.
Scheduled sale ($1.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DFTX | SELL | 2026-03-26 | $451K | — | Filing → |
| MNMD | SELL | 2025-12-29 | $678K | — | Filing → |
| MNMD | SELL | 2025-09-26 | $504K | — | Filing → |